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     Circulating microRNAs (miRNAs) are receiving attention as potential biomarkers of 
various diseases, including cancers, chronic obstructive pulmonary disease, and 
cardiovascular disease. However, it is unknown whether the levels of circulating miRNAs in a 
healthy subject might vary with external factors in daily life. In this study, we investigated 
whether cigarette smoking, a habit that has spread throughout the world and is a risk factor for 
various diseases, affects plasma miRNA profiles. We determined the profiles of 11 smokers 
and 7 non-smokers by TaqMan MicroRNA array analysis. A larger number of miRNAs were 
detected in smokers than in non-smokers, and the plasma levels of two thirds of the detected 
miRNAs (43 miRNAs) were significantly higher in smokers than in non-smokers. A principal 
component analysis of the plasma miRNA profiles clearly separated smokers and 
non-smokers. Twenty-four of the miRNAs were previously reported to be potential 
biomarkers of disease, suggesting the possibility that smoking status might interfere with the 
diagnosis of disease. Interestingly, we found that quitting smoking altered the plasma miRNA 
profiles to resemble those of non-smokers. These results suggested that the differences in the 
plasma miRNA profiles between smokers and non-smokers could be attributed to cigarette 
smoking. In addition, we found that an acute exposure of ex-smokers to cigarette smoke 
(smoking one cigarette) did not cause a dramatic change in the plasma miRNA profile. In 
conclusion, we found that repeated cigarette smoking substantially alters the plasma miRNA 









MicroRNAs (miRNAs) are a class of endogenous, short non-coding RNAs 19-25 
nucleotides in length that negatively regulate gene expression via translational repression or 
mRNA degradation, primarily by pairing with the 3’-untranslated regions of the target 
mRNAs (Ambros, 2001). More than 2,000 human miRNAs have been identified (miRBase 
ver. 19). It is now clear that miRNAs are involved in various important biological processes, 
including cell differentiation, proliferation, apoptosis, and development (He et al., 2004; 
Meltzer et al., 2005). Some miRNAs are expressed in a tissue-specific manner, and others are 
ubiquitously expressed (Liang et al., 2007). It is also known that miRNA expression is 
significantly altered in several diseases (http://www.miR2disease.org/), and the dysregulation 
of miRNAs is closely linked with the incidence or progress of these diseases. 
It was reported in 2008 that miRNAs exist in plasma or serum (Mitchell et al., 2008). 
Subsequent reports have revealed the presence of miRNAs in saliva (Park et al., 2009; 
Michael et al., 2010) and urine (Hanke et al., 2010). These extracellular miRNAs are stable in 
the RNase-rich environment because they are enclosed in vesicles, including exosomes, 
microvesicles, apoptotic bodies, and ectosomes (Lee et al., 2012), or are associated with 
RNA-binding proteins, including nucleophosmin 1 (Wang K et al., 2010) or high-density 
lipoprotein (Vickers et al., 2011). Following the discovery of extracellular miRNA in body 
fluids, a significant number of papers reported that the levels of some extracellular miRNAs 
are linked to different pathophysiological conditions. Examples of this include the 
associations of miR-141 and miR-375 with prostate cancer (Bryant et al., 2012), miR-29a and 
miR-92a with colorectal cancer (Huang et al., 2010), miR-499 with myocardial infarction 
(Olivieri et al., in press), and miR-122 with liver injury (Wang et al., 2009). These findings 
introduce the possibility of using the levels of specific miRNAs in body fluids as biomarkers 
for different pathological conditions (Wang K. et al., 2012; Duttagupta et al., 2011). However, 
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it is unknown whether the levels of extracellular miRNAs in a healthy subject might vary with 
external factors in daily life. 
Cigarette smoking is a habit that has spread all over the world and is a significant risk 
factor for many diseases, including lung cancer (Shields et al., 1999), chronic obstructive 
pulmonary disease (Higgins et al., 1984), asthma (Ulrik et al., 2001) and cardiovascular 
disease (Holbrook et al., 1984). Cigarette smoke contains over 4,800 chemicals, including 69 
carcinogens (Hoffmann et al., 2001), which appear to be of crucial importance in causing 
disease. We questioned whether cigarette smoking alters plasma miRNA profiles in humans, 
and, if it does, whether the changes may be associated with the pathogenesis of various 
diseases. In this study, we compared the plasma miRNA profiles of smokers and non-smokers 
and discussed the biological significance of the different profiles by the smoking status. 
 
Materials and methods 
 
Chemicals and reagents. The mirVana PARIS Kit, Megaplex pools, TaqMan microRNA 
Reverse Transcription Kit,TaqMan Universal PCR Master Mix (No AmpErase UNG) and 
TaqMan Human MicroRNA Array A and B Card v2.0 were from Life Technologies 
(Carlsbad, CA). Nicotine and cotinine were purchased from Sigma (St. Louis, MO). 
Acetanilide was purchased from Wako (Osaka, Japan). All other chemicals and solvents were 
of the highest grade commercially available. 
 
Study design.  This study was approved by the Ethics Committee of Kanazawa University 
(Kanazawa, Japan). Written, informed consent was obtained from all the subjects. Eleven 
smokers (S1 - S11) and seven non-smokers (NS1 - NS7) who were healthy male Japanese 
taking no medicines or supplements were recruited (Table 1). The smokers smoked their 
favorite brands of cigarettes as shown in Table 1. The pack year (number of cigarettes per day 
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× number of years smoked / 20 cigarettes in one pack) ranged from 4 to 35 (18 ± 9). There 
were no significant differences in the age and body weight of the smokers and non-smokers.  
     This study consists of three experiments. For the blood collection (5 ml), subjects came at 
10 AM without having had breakfast. In experiment I, blood was collected from all subjects 
to compare the plasma miRNA profiles in smokers and non-smokers. Smoking occurred in 
the morning or not, according to each smoker’s habit. After experiment I, we noticed that four 
smokers (S1, S2, S4, and S8) had voluntarily quit smoking. Among them, subject S8 had used 
nicotine patches after experiment I. In experiment II, blood was collected from the four 
subjects to determine their plasma miRNA profiles after they quit smoking (S1, S2, and S4 
were tested one month after quitting; S8 was tested three months after quitting but was using 
nicotine patches). After that, two subjects, S1 and S4, returned to smoking. We had asked 
them to contact us when they began smoking again. In experiment III, blood was collected 
from the two subjects (S1 and S4) 20 min after they smoked the first cigarette (MILD SEVEN, 
Japan Tobacco, Tokyo, Japan) to determine the plasma miRNA profiles immediately after 
exposure to cigarette smoke.
  
RNA isolation from plasma.  Ethylenediamine-N,N,N’,N’-tetraacetic acid disodium salt was 
added as an anticoagulant to the blood, which was then kept at room temperature for 30 min. 
After centrifugation at 3,000 g for 10 min at 4°C, the plasma was collected. Immediately, total 
RNA was isolated from 600 µl of plasma using the mirVana PARIS kit as described 
previously (Yamaura et al., 2012). 
 
Taqman microRNA array analysis.  The expression profiles of miRNAs were assessed using 
TaqMan Human MicroRNA Array A+B Cards Sets v2.0 containing 377 (A array) or 285 (B 
array) primer-probe sets for individual miRNAs (total 662 miRNAs). All procedures were 
performed following the manufacturer’s instruction. Briefly, 3 µl of total RNA was reverse 
 6 
transcribed using Megaplex RT Primer Pool A or B and TaqMan MicroRNA Reverse 
Transcription Kits. Pre-amplification was carried out using Megaplex PreAmp primers and 
the TaqMan Preamp Master Mix. The expression of miRNAs was determined by quantitative 
real-time PCR using the TaqMan Human MicroRNA Array with the 7900HT Fast Real-Time 
PCR System (Life Technologies) and the manufacturer’s recommended cycling conditions. 
Cycle threshold (Ct) values were calculated using the SDS software v.2.3 with a baseline of 
3-15 and an assigned minimum threshold of 0.2. Expression of miRNAs was normalized by 
global normalization, which implicitly assumes that the mean expression level of all 
monitored miRNAs is constant. Any miRNA giving 40-Ct < 8, a cutoff value recommended 
by the manufacturer, in at least one sample was omitted from the data analysis. 
  
Principal component analysis.  The plasma miRNA expression data were analyzed using the 
Partek Genomics Suite version 6.12 (Partek, St. Louis, MO). Principal component analysis 
(PCA) was performed to visualize the difference between groups of the expression profiles of 
miRNAs that exceeded the cutoff value. 
 
Measurement of plasma concentrations of nicotine and cotinine. Plasma concentrations of 
nicotine and cotinine were measured as described previously (Nakajima et al., 2000) with 
slight modifications. The plasma sample (0.5 ml) was alkalinized with 25 µl of 10 M NaOH. 
After the addition of 10 µl of 7 µM acetanilide as an internal standard, the mixture was 
extracted with 4 ml dichloromethane by shaking for 10 min. After centrifugation at 1,000 g 
for 10 min, 12 µl of 12 M HCl was added to the organic fraction. The organic fraction was 
evaporated with a vacuum evaporator at 40°C. The residue was redissolved in 50 µl of the 
mobile phase, and then a 20 µl portion of the sample was subjected to liquid 
chromatography/tandem mass spectrometry (LC-MS/MS). The LC-MS/MS condition was 
described in our previous report (Yamanaka et al., 2004).
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Statistical analysis.  Data are presented as the mean ± standard deviation. Statistical analyses 
of the differences between two groups were performed by an unpaired two-tailed Student’s 




Plasma miRNA profiles of non-smokers and smokers 
We determined plasma miRNA expression in 11 smokers and 7 non-smokers by 
quantitative real-time PCR using the TaqMan MicroRNA Array. The numbers of miRNAs 
with 40-Ct > 8 in each individual are shown in Table 2. The numbers in smokers (196 ± 18) 
were significantly (P < 0.001) larger than those in non-smokers (143 ± 29). The number of 
miRNAs that exceeded the cutoff value in all subjects (n = 18) was 66. We compared the 
levels of 66 miRNAs in smokers and non-smokers. Among them, 44 miRNAs showed a 
significant difference between the groups (Table 3). Forty-three miRNAs were higher in 
smokers than in non-smokers, whereas 1 miRNA was lower in smokers than in non-smokers. 
To visualize the difference in the expression profiles of miRNAs between smokers and 
non-smokers, PCA was performed using the expression data for the 66 miRNAs. PC1 
encompassed a significantly large proportion (63%) of the total variance for each subject, 
followed by PC2 (10%) and PC3 (6%). As shown in Fig. 1, the profiles of plasma miRNA 
expression of the smokers were different from those of the non-smokers. 
 
Quitting smoking altered the plasma miRNA profile 
     To investigate whether the difference in the plasma miRNA profiles between smokers and 
non-smokers was due to cigarette smoking, we examined miRNA expression in the plasma of 
4 smokers who had stopped smoking (S1, S2, S4, and S8). To confirm their non-smoking 
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status, we measured their plasma concentrations of nicotine and cotinine. For comparison, 
nicotine and cotinine concentrations were also measured when they were still smoking 
(experiment I); these concentrations were 3.6 - 26.0 ng/ml and 23.4 - 413.0 ng/ml, 
respectively (Table 4). One month after they stopped smoking, the levels in S1 and S2 had 
dramatically decreased to values close to the detection limit. In the plasma from S4, low 
levels of nicotine and cotinine were detected; therefore, he might have been smoking in secret 
or been exposed to passive smoking. S8 showed substantial nicotine and cotinine levels 
comparable to those of active smokers. These levels were not surprising because this subject 
used nicotine patches.  
     The numbers of miRNAs with 40-Ct > 8 in the 4 subjects who had stopped smoking were 
141 ± 13 (129 - 160). Interestingly, the number was very close to that in non-smokers (143 ± 
29) and was significantly (P < 0.01) lower than that when they were still smoking (209 ± 21) 
(Table 2). We compared the plasma miRNA expression in the four subjects before and after 
they stopped smoking. The numbers of miRNAs that exceeded the cutoff value in the four 
subjects was 93. Among them, 63 miRNAs showed a significant difference between the 
groups (Table 5). Sixty miRNAs were significantly lower after the subjects had stopped 
smoking than before they stopped, whereas 3 miRNAs were significantly higher after they 
stopped than before they stopped. Interestingly, among the 60 miRNAs that were lower after 
the subjects had stopped smoking, 38 miRNAs (shaded in Table 5) were the ones more highly 
expressed in smokers than in non-smokers (Table 2). These results suggested that the plasma 
miRNA expression is unambiguously affected by smoking.  
     We considered the possibility that quitting smoking might alter the plasma miRNA 
profiles to resemble the profiles of non-smokers. To test this possibility, we compared the 
plasma miRNA profiles of the 4 subjects before and after they stopped smoking, as well as 
the profiles of the 7 non-smokers. The number of miRNAs exceeding the cutoff value among 
the three groups was 66. PCA was performed using the expression data of the 66 miRNAs 
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(Fig. 2A). PC1 encompassed the largest proportion (60%) of the total variance for each 
subject, followed by PC2 (10%) and PC3 (6%). These results clearly demonstrated that the 
plasma miRNA profiles of smokers were altered after they stopped smoking, and the profiles 
then resembled those of non-smokers. 
 
Smoking one cigarette does not cause a dramatic change in the expression of plasma miRNAs
To ascertain how quickly the plasma miRNA profile was changed by smoking, we 
examined plasma miRNA profiles 20 min after 2 ex-smokers (S1 and S4) had each smoked 
one cigarette. We chose this time because it is near the Cmax values of nicotine and cotinine 
after smoking (Yamanaka et al., 2004). The plasma concentrations of nicotine after one 
cigarette were 13.7 ng/ml and 15.7 ng/ml, and those of cotinine were 5.1 ng/ml and 17.9 
ng/ml (Table 4), suggesting that the subjects had inhaled the cigarettesmoke. The numbers of 
miRNAs with 40-Ct > 8 were 177 and 131, slightly larger than the numbers of miRNAs prior 
to smoking the cigarettes (Table 2). The miRNA expression data were included in the PCA 
for the 66 miRNAs described above. As shown in Fig. 2B, the miRNA profiles after smoking 
one cigarette were similar to those of the smokers who had stopped smoking and the 
non-smokers. These results suggest that changes in the plasma miRNA profiles in smokers 




Circulating miRNAs have received considerable attention as potential biomarkers of 
various diseases (Reid et al., 2011) based on many studies reporting differences in plasma or 
serum miRNA levels between healthy subjects and patients. However, it remains unclear to 
what extent the circulating miRNA profiles in healthy subjects vary in daily life due to 
changes in diet, supplements, alcohol intake, cigarette smoking, exposure to environmental 
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chemicals, sleeping or circadian rhythm, stress, and exercise or other factors. In the present 
study, we focused on cigarette smoking because it is a habit spread all over the world and is a 
significant risk factor for various diseases including cancer. In the present investigation of the 
plasma miRNA profiles of smokers and non-smokers, the subjects were limited to men 
because a study had reported subtle sex differences (Ji et al., 2009), although another study 
reported no large sex differences in plasma miRNA expression (Chen et al., 2008), and 
because smoking is more prevalent in men than in women in Japan. In addition, considering 
the potential effects of circadian rhythm (Shende et al., 2011), we standardized the time of 
blood collection. 
We found that a larger number of miRNAs were detected in smokers than in 
non-smokers, and the plasma levels of two thirds of the detected miRNAs (43 miRNAs) were 
significantly higher in smokers than in non-smokers (Table 3). Interestingly, we found that 
quitting smoking changed the plasma miRNA profiles resembling those of the non-smokers 
(Fig. 2A). These results suggested that the differences in the plasma miRNA profiles of 
smokers and non-smokers were actually due to cigarette smoking. However, no association 
was observed between the numbers of detected miRNAs or abundance of miRNAs and 
plasma nicotine or cotinine levels or smoking history within smokers (data not shown). One 
subject who stopped smoking, S8, was a nicotine patch user. Because there was no substantial 
difference between the plasma miRNA profile of this subject and those of the other 3 subjects 
who stopped smoking, as well as those of the non-smokers, nicotine is unlikely to cause 
altered plasma miRNA expression. Other chemicals or oxidants in cigarette smoke, or 
hypoxic stress, might cause changes in plasma miRNA profiles. It would be of interest to 
investigate whether the miRNAs whose levels were higher in smokers than in non-smokers 
might be positively correlated with plasma levels of oxidative stress markers such as 
8-hydroxydeoxyguanosine or malondialdehyde in smokers.  It has been reported that the 
plasma levels of these markers were approximately 1.5 times higher in smoker than in 
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non-smokers (Yamaguchi et al., 2005, Bloomer, 2007). Interestingly, Yamaguchi et al (2005) 
reported that the levels of these oxidative stress markers were further increased within 30 min 
by smoking one cigarette after quitting smoking at least 10 hr. The results were in contrast to 
our finding for miRNAs that the exposure to one cigarette smoke did not substantially change 
the plasma miRNA profile.  In addition, our finding is inconsistent with a previous study 
reporting that urinary genotoxicity was detected 2 hr after smoking one cigarette (De Flora et 
al., 1996). Although miR-210 and miR-373 are known to be typical miRNAs whose 
expression in cells was changed in response to hypoxia (Crosby et al., 2009), the levels of 
these miRNAs in plasma were below the cutoff values in both of smokers and non-smokers in 
our study. Collectively, there might be a time lag between the changes of intracellular miRNA 
expression and those of extracellular miRNA levels. Alternatively, consecutive and/or 
dynamic change of intracellular miRNA expression might be required to be reflected to the 
change of extracellular miRNA levels. We claim that the differences in the plasma miRNA 
profiles between smokers and non-smokers could be attributed to repeated smoking. An 
understanding of the number of cigarettes or the frequency of smoking required to cause 
changes in plasma miRNA profiles is left for future studies. 
It is generally accepted that extracellular miRNAs mirror changes in miRNA 
expression in cells or tissues (Lee et al., 2012). There are some reports of the effects of 
cigarette smoke on miRNA expression in tissues (De Flora et al., 2012). Exposure to cigarette 
smoke caused down-regulation of some miRNAs in mouse and rat lungs (Izzotti et al., 2009a, 
2009b), and the down-regulation in mouse lung was reversed by smoking cessation (Izzotti et 
al., 2011). Similar findings have been reported in humans; the levels of several miRNAs in 
airway epithelium (Schembri et al., 2009), placenta (Maccani et al., 2010), and alveolar 
macrophages (Graff et al., 2012) were lower in smokers than in non-smokers. These results 
lead us to speculate that miRNAs in tissues, including trachea and lung, exposed to cigarette 
smoke might leak into blood. This might be the reason for higher levels of circulating 
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miRNAs in smokers. Although it is not known whether extracellular miRNAs are functional, 
miRNAs undoubtedly function in cells; therefore, changes in miRNA expression in tissues or 
cells caused by exposure to cigarette smoke may have some pathophysiological significance. 
Integrated analysis of the expression of circulating miRNAs and the dysregulation of miRNAs 
and their target genes in tissues could provide insight into the initiation and progression of 
smoking-related diseases. 
Interestingly, we noticed that 24 of the 44 miRNAs that showed a significantly different 
expression between smokers and non-smokers were previously reported as potential 
biomarkers of diseases (Table 6). Our observations show that smoking status might lead to 
incorrect conclusions when circulating miRNAs are used as biomarkers of diseases. Smoking 
status should therefore be considered when using circulating miRNAs as biomarkers of 
disease. 
In conclusion, we found that cigarette smoking unambiguously alters plasma miRNA 
profiles. A larger number of miRNAs were detected and their expression levels were higher in 
smokers than in non-smokers. Because more than half of the miRNAs were reported to be 
potential biomarkers of diseases, we suggest the possibility that smoking status might 
complicate diagnosis. The plasma miRNA profiles that mirror changes in miRNA expression 
in tissues might signal smoking-related diseases. The information presented here provides 
new insight into an area of future research on circulating miRNAs. 
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Table 1. Characteristics of subjects. 





 Brand of cigarette Nicotine (mg) 
Tar 
(mg) 
Age at starting 
smoking (years) 
Number of 
cigarettes per day 
Number of years 
smoked (years) Pack-year 
S1 36 168 50  MILD SEVEN 0.7 8 
 
20 15 16 12 
S2 41 170 64  MILD SEVEN LIGHTS 0.7 8  20 20 21 21 
S3 35 169 65  MILD SEVEN 0.8 10  20 30 15 23 
S4 55 177 68  Marlboro 1.0  12  20 20 35 35 
S5 21 172 80  Hi-Lite menthol 0.7 10  16 15  5 4 
S6 46 165 53  Hi-Lite 1.4 17  20 20 26 26 
S7 38 167 57  MILD SEVEN AQUA menthol 0.1 1  20 10 18 9 
S8 37 165 58  LARK menthol 0.1 1  20 20 17 17 
S9 40 156 53  CABIN 0.4 5  18 20 22 22 
S10 36 172 55  MILD SEVEN super LIGHTS 0.5 6  20 20 16 16 
S11 39 168 65 KOOL mild 0.7 8 16 10 23 12 
Mean ± SD 38.5 ± 8.2 168 ± 5.0 61.7 ± 8.7 
 
  0.6 ± 0.4 8 ± 5 
 
  18 ± 6 19 ± 8 18 ± 9 
NS1 26 163 65          
NS2 39 177 84          
NS3 50 164 63          
NS4 29 169 62          
NS5 41 173 80          
NS6 43 161 57          
NS7 28 170 67          
Mean ± SD 36.6 ± 9.0 168.1 ± 5.8 68.3 ± 9.9                 
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Table 2. The numbers of plasma miRNAs with 40-Ct > 8 in non-smokers (NS) and smokers (S). 




  Smoking Quit Acute exposure 
NS1 174  S1 198  198 160 177 
NS2 191  S2 216  216 138  
NS3 138  S3 208     
NS4 138  S4 234  234 129 131 
NS5 110  S5 189     
NS6 121  S6 189     
NS7 129  S7 185     
   S8 187  187 137  
   S9 177     
   S10 170     
     S11 200      
Mean ± SD 143 ± 29   Mean ± SD  196 ± 18***   209 ± 21 141 ± 13##   
***P < 0.001, compared with non-smokers.  
















Table 3. Forty-four plasma miRNAs are differently (P < 0.05) expressed in 7 non-smokers 
(NS) compared to 11 smokers (S). 
40 - Ct value (Mean ± SD) microRNA NS S Fold (S/NS) P-value 
miR-374b 12.75 ± 2.89 15.76 ± 1.03 8.11  0.006 
miR-331-3p 11.72 ± 2.85 14.61 ± 1.26 7.39  0.009 
miR-221 12.84 ± 2.46 15.61 ± 1.57 6.83  0.010 
let-7g 12.85 ± 1.78 15.40 ± 0.89 5.89  0.001 
miR-301a 10.66 ± 1.79 13.09 ± 0.78 5.39  0.001 
let-7e 15.47 ± 1.07 17.74 ± 1.13 4.83  0.001 
miR-335 11.21 ± 1.94 13.48 ± 0.80 4.83  0.003 
miR-26a 14.91 ± 1.45 17.09 ± 0.91 4.51  0.001 
miR-30c 15.21 ± 1.13 17.35 ± 0.82 4.40  0.000 
miR-185 10.65 ± 2.06 12.77 ± 0.67 4.36  0.005 
miR-374a 13.71 ± 1.50 15.83 ± 0.96 4.36  0.002 
miR-30b 15.24 ± 1.20 17.36 ± 0.76 4.33  0.000 
let-7b 14.33 ± 1.06 16.43 ± 0.94 4.30  0.000 
miR-451 15.62 ± 1.75 17.70 ± 1.61 4.22  0.020 
miR-27a 12.36 ± 2.02 14.26 ± 0.48 3.74  0.008 
miR-29a 12.78 ± 1.32 14.64 ± 0.43 3.63  0.000 
miR-191 18.18 ± 1.79 20.04 ± 0.87 3.63  0.009 
miR-26b 14.15 ± 1.33 15.99 ± 0.75 3.59  0.002 
miR-199a-3p 14.49 ± 1.54 16.30 ± 0.82 3.52  0.005 
miR-425 12.11 ± 1.50 13.92 ± 0.78 3.51  0.004 
miR-223 21.95 ± 1.59 23.70 ± 0.45 3.36  0.003 
miR-328 13.18 ± 1.91 14.87 ± 0.94 3.23  0.023 
miR-21 14.41 ± 1.42 16.06 ± 0.38 3.14  0.002 
let-7d 13.32 ± 0.94 14.97 ± 0.91 3.12  0.002 
miR-19b 18.36 ± 1.39 20.00 ± 0.56 3.12  0.003 
miR-106b 13.34 ± 1.71 14.92 ± 0.82 2.99  0.017 
miR-19a 14.53 ± 1.29 16.10 ± 0.53 2.96  0.002 
miR-186 15.79 ± 1.55 17.33 ± 0.60 2.92  0.008 
miR-93 14.99 ± 1.67 16.44 ± 0.73 2.72  0.021 
miR-454 14.12 ± 1.00 15.52 ± 0.88 2.64  0.007 
miR-345 11.46 ± 1.29 12.86 ± 0.71 2.63  0.009 
miR-20b 15.24 ± 1.44 16.60 ± 0.36 2.57  0.008 
miR-17 18.67 ± 1.31 19.89 ± 0.50 2.33  0.013 
miR-20a 18.08 ± 1.31 19.29 ± 0.58 2.32  0.015 
miR-24 18.26 ± 1.58 19.43 ± 0.74 2.25  0.048 
miR-106a 18.58 ± 1.43 19.75 ± 0.56 2.25  0.026 
miR-126 19.24 ± 1.06 20.41 ± 0.75 2.24  0.015 
miR-16 20.12 ± 1.09 21.26 ± 0.78 2.19  0.020 
miR-25 13.92 ± 1.18 15.04 ± 0.68 2.18  0.020 
miR-923 13.19 ± 1.59 14.31 ± 0.58 2.16  0.016 
miR-195 14.69 ± 1.10 15.79 ± 0.91 2.14  0.035 
miR-126* 16.28 ± 1.02 17.33 ± 0.58 2.07  0.013 
miR-92a 17.36 ± 0.81 18.12 ± 0.64 1.70  0.039 
miR-188-5p 12.90 ± 0.95 12.05 ± 0.74 0.55  0.047 
Plasma miRNAs shaded with gray have been reported to be candidate biomarkers of 
diseases (Table 6).
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Table 4. Plasma concentrations of nicotine and cotinine in 4 smokers who quit smoking for at least 
one month and then smoked again. 
  Nicotine (ng/ml)   Cotinine (ng/ml) 
Status  Status 
Smoker 
Smoking Quit Acute exposure  Smoking Quit Acute exposure 
S1  3.6 0.1 13.7  282.1 1.1 5.1 
S2 16.3 1.0   23.4 0.6  
S4 16.7 3.3 15.7  413.0 9.5 17.9 























Table 5. Sixty-three plasma miRNAs differently (P < 0.05) expressed in 4 subjects 
(S1, S2, S4, and S8) who smoked (S) and then quit smoking (Q). 
40 - Ct values (Mean ± SD) microRNA S Q Fold (Q/S) P-value 
hsa-miR-766 15.07 ± 1.48 10.44 ± 0.92 0.04  0.002 
hsa-miR-374b 16.30 ± 0.47 11.73 ± 0.87 0.04  0.000 
hsa-miR-340 13.41 ± 0.32  9.64 ± 1.05 0.07  0.000 
hsa-let-7e 18.30 ± 1.06 14.57 ± 0.50 0.08  0.001 
hsa-miR-191 20.53 ± 0.80 16.85 ± 0.65 0.08  0.000 
hsa-miR-103 13.99 ± 1.22 10.34 ± 1.98 0.08  0.020 
hsa-miR-199a-3p 16.67 ± 0.91 13.13 ± 0.46 0.09  0.000 
hsa-miR-625* 14.33 ± 1.50 10.83 ± 0.53 0.09  0.005 
hsa-miR-186 17.45 ± 0.47 14.01 ± 0.96 0.09  0.001 
hsa-let-7g 15.68 ± 0.86 12.25 ± 1.41 0.09  0.006 
hsa-miR-185 12.85 ± 0.54  9.43 ± 0.84 0.09  0.000 
hsa-miR-197 15.88 ± 0.97 12.52 ± 1.36 0.10  0.007 
hsa-miR-331-3p 15.43 ± 0.91 12.19 ± 0.76 0.11  0.002 
hsa-miR-454 15.71 ± 0.91 12.50 ± 0.33 0.11  0.001 
hsa-miR-374a 16.15 ± 0.49 12.95 ± 0.84 0.11  0.001 
hsa-let-7b 16.62 ± 1.04 13.52 ± 0.70 0.12  0.003 
hsa-miR-495 12.63 ± 0.42  9.54 ± 0.76 0.12  0.000 
hsa-let-7d 15.36 ± 0.78 12.44 ± 0.70 0.13  0.001 
hsa-miR-484 19.64 ± 0.80 16.77 ± 0.94 0.14  0.004 
hsa-miR-19a 16.28 ± 0.18 13.51 ± 0.99 0.15  0.001 
hsa-miR-301a 13.38 ± 0.62 10.65 ± 0.76 0.15  0.001 
hsa-miR-26a 17.63 ± 0.70 14.93 ± 0.95 0.15  0.004 
hsa-miR-151-3p 15.05 ± 1.23 12.35 ± 0.30 0.15  0.005 
hsa-miR-335 13.88 ± 0.77 11.21 ± 0.54 0.16  0.001 
hsa-miR-181a 17.87 ± 1.20  9.21 ± 0.84 0.16  0.011 
hsa-miR-222 19.08 ± 0.74 16.44 ± 1.15 0.16  0.008 
hsa-miR-28-3p 14.60 ± 0.79 11.98 ± 1.10 0.16  0.008 
hsa-miR-590-5p 14.43 ± 0.24 11.82 ± 0.26 0.16  0.000 
hsa-miR-140-5p 15.85 ± 0.76 13.28 ± 0.67 0.17  0.002 
hsa-miR-30b 17.77 ± 0.51 15.20 ± 0.83 0.17  0.002 
hsa-miR-30d 12.03 ± 1.26  9.47 ± 0.98 0.17  0.018 
hsa-miR-15b 15.56 ± 0.58 13.03 ± 0.78 0.17  0.002 
hsa-miR-20b 16.63 ± 0.30 14.14 ± 0.82 0.18  0.001 
hsa-miR-93 16.81 ± 0.69 14.38 ± 0.92 0.19  0.006 
hsa-miR-223 23.87 ± 0.27 21.45 ± 0.45 0.19  0.000 
hsa-miR-342-3p 17.36 ± 0.42 15.00 ± 0.10 0.19  0.007 
hsa-miR-320 18.79 ± 0.88 16.45 ± 0.71 0.20  0.006 
hsa-miR-28-5p 12.55 ± 0.73 10.23 ± 1.06 0.20  0.011 
hsa-miR-328 15.56 ± 0.91 13.25 ± 0.08 0.20  0.002 
hsa-miR-24 19.90 ± 0.65 17.63 ± 0.52 0.21  0.002 
hsa-miR-126 20.70 ± 0.57 18.57 ± 0.49 0.23  0.001 
hsa-miR-26b 16.19 ± 0.33 14.07 ± 0.80 0.23  0.003 
hsa-miR-152 12.97 ± 0.65 10.89 ± 0.19 0.24  0.022 
hsa-miR-27a 14.50 ± 0.37 12.51 ± 0.29 0.25  0.000 
hsa-miR-17 20.04 ± 0.45 18.05 ± 0.65 0.25  0.002 
hsa-miR-30c 17.78 ± 0.66 15.82 ± 0.90 0.26  0.013 
hsa-miR-19b 20.02 ± 0.28 18.21 ± 0.72 0.28  0.003 
hsa-miR-106a 19.90 ± 0.63 18.09 ± 0.39 0.29  0.003 
hsa-miR-20a 19.41 ± 0.36 17.61 ± 0.48 0.29  0.001 
hsa-miR-923 14.40 ± 0.85 12.66 ± 0.88 0.30  0.030 
hsa-miR-29a 14.62 ± 0.48 12.93 ± 0.33 0.31  0.001 
hsa-miR-345 13.14 ± 0.88 11.46 ± 0.61 0.31  0.020 
hsa-miR-18a 13.32 ± 0.53 11.64 ± 0.23 0.31  0.001 
hsa-miR-106b 14.88 ± 0.22 16.42 ± 0.43 0.36  0.001 
hsa-miR-16 21.06 ± 0.45 19.60 ± 0.65 0.36  0.010 
hsa-miR-126* 17.04 ± 0.35 15.60 ± 0.95 0.37  0.029 
hsa-miR-532-5p 12.25 ± 0.76 10.83 ± 0.53 0.37  0.022 
hsa-miR-148a 12.15 ± 0.66 10.90 ± 0.78 0.42  0.050 
hsa-miR-92a 18.31 ± 0.42 17.07 ± 0.65 0.42  0.019 
hsa-miR-21 15.98 ± 0.36 14.81 ± 0.65 0.45  0.020 
hsa-miR-135a* 15.80 ± 0.88 17.06 ± 0.39 2.39  0.039 
hsa-miR-188-5p 11.68 ± 0.45 13.20 ± 0.12 2.86  0.001 
hsa-miR-138-1* 11.61 ± 1.31 14.36 ± 0.21 6.73  0.006 
Plasma miRNAs shaded with gray were more highly expressed in smokers than in 
non-smokers (Table 3). 
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Table 6. Circulating miRNAs reported to be potential biomarkers of diseases in humans. 
miRNA Disease 
hsa-miR-221 Colorectal cancer↑ (Pu et al., 2010), Malignant melanoma↑ (Kanemaru et al., 2011) 
let-7g Breast cancer↑(Cookson et al., 2012) 
hsa-let-7e Papillary thyroid carcinomas↑(Yu et al., 2012) 
hsa-miR-26a Pancreatic cancer↑(Mahn et al., 2011), Type 1 diabetes↑(Nielsen et al., in press) 
hsa-miR-30c Acute myocardial infarction↑(Meder et al., 2011) 
hsa-let-7b Acute myocardial infarction↑(Long et al., 2012b) 
hsa-miR-451 Systemic lupus erythematosus↑(Wang H. et al., 2012), Renal cell carcinoma↓(Redova et al., 2012) 
hsa-miR-27a Type 1 diabetes↑(Nielsen et al., in press) 
hsa-miR-29a Type 1 diabetes↑(Nielsen et al., in press), Active pulmonary tuberculosis↑(Fu et al., 2011), Colorectal cancer↑(Huang et al., 2010) 
hsa-miR-191 Type 2 diabetes↓(Zampetaki et al., 2010) 
hsa-miR-223 Nasopharyngeal carcinoma↑(Zeng et al., 2012), Systemic lupus erythematosus↑(Wang H. et al., 2012), Gastric cancer↑(Li et al., 2010) 
 Hepatocellular carcinoma↑(Qi et al., 2011; Xu et al., 2011), Type 2 diabetes↓(Zampetaki et al., 2010), Sepsis↓(Wang J.F. et al., 2010) 
hsa-miR-328 Acute myocardial infarction↓(Wang et al., 2011) 
hsa-miR-21 Breast cancer↑(Si et al., in press), Aortic stenos↑(Villar et al., in press), Esophageal squamous cell carcinoma↑(Komatsu et al., 2011) 
 Non-small cell lung cancer↑(Wei et al., 2011), Gastric cancer↑(Li et al., 2010; Zheng et al., 2011-2012) 
hsa-miR-106b Gastric cancer↑(Tsujiura et al., 2010) 
hsa-miR-20b Non-small cell lung cancer↓(Silva et al., 2011) 
hsa-miR-17 Nasopharyngeal carcinoma↓(Zeng et al., 2012) 
hsa-miR-20a Non-small cell lung cancer↓(Silva et al., 2011) 
hsa-miR-24 Type 1 diabetes↑(Nielsen et al., in press), Type 2 diabetes↓(Zampetaki et al., 2010) 
hsa-miR-106a Gastric cancer↑(Tsujiura et al., 2010) 
hsa-miR-126 Acute myocardial infarction↑(Long et al., 2012a), Type 2 diabetes↓(Zampetaki et al., 2010) 
hsa-miR-16 Hepatocellular carcinoma↓(Qu et al., 2011) 
hsa-miR-25 Type 1 diabetes↑(Nielsen et al., in press) 
hsa-miR-195 Acute myocardial infarction↑(Long et al., 2012b), Breast cancer↑(Heneghan et al., 2010) 







Fig. 1. PCA of plasma miRNA expression in 7 non-smokers (NS) and 11 smokers (S). PCA 
was performed using 66 miRNAs that exceeded the cutoff value in all subjects (n = 18). A 
three-component model was developed that explained a total of 79% (PC1, 63%; PC2, 10%; 
PC3, 6%) of the variability of the data. Each ball representing an individual is connected to 
the centroid (marked as NS or S) of each group. The numbers near the balls represent the 
subject number. This plot illustrates the level of spread between individuals and groups using 
three principal components. 
 
Fig. 2. The effects of quitting smoking and of subsequently smoking one cigarette on plasma 
miRNA profiles. (A) PCA was performed using 66 miRNAs that exceeded the cutoff value in 
4 subjects who smoked and who quit smoking, as well as in 7 non-smokers. A 
three-component model was developed explaining a total of 76% (PC1, 60%; PC2, 10%; PC3, 
6%) of the variability of the data. Each ball representing an individual is connected to the 
centroid (marked as NS, S, or Q) of each group. The numbers near the balls represent the 
subject number. (B) PCA for the expression of 66 miRNAs in 4 groups: 4 subjects who 
smoked and who quit smoking, 7 non-smokers and 2 subjects who quit smoking but then 
smoked one cigarette. A three-component model was developed explaining a total of 74% 
(PC1, 58%; PC2, 10%; PC3, 6%) of the variability of the data. Each ball representing an 
individual is connected to the centroid (marked as NS, S, Q, or A) of each group. 
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